The Advanced Research Projects Agency for Health (ARPA-H) unveiled two multi-million-dollar initiatives, THRIVE and GIVE, aimed at accelerating development and manufacturing of custom gene editing therapies for rare diseases. These programs seek to enable rapid, patient-specific CRISPR treatments and localized production units, respectively, expanding access beyond single-case successes. The efforts align with upcoming regulatory frameworks from the FDA and represent a major investment in personalized genomic medicine infrastructure.